← Evidence map

ArticleChina CDC weekly2025

Post-Marketing Surveillance of Adverse Events Following Recombinant Zoster Vaccine - China, 2020-2023.

Yan Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

3 papers cite it

2025
2026
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 40376254